14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
MTNB vs ABBV: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Abbvie Inc. (ABBV) is the stronger overall head-to-head candidate over Matinas BioPharma Holdings, Inc. (MTNB) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MTNB carries a Unified Composite Score of 54.6/100 (HOLD) at $0.81 (N/M Forward P/E, 0.0% operating margin), whereas ABBV carries 53.5/100 (HOLD) at $283.54 (17.4x Forward P/E, 36.6% operating margin).
Composite vs. Pillar Nuance: While MTNB currently prints a higher short-term Unified Composite Score (54.6/100 HOLD vs. ABBV 53.5/100 HOLD), ABBV captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (36.6% vs. 0.0% operating margin) and revenue trajectory (+10.3% vs. -100.0% YoY).
Competes within the Biotechnology value chain with $979,904 market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
ABBV Moat ProfileHigh-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $505.6B market capitalization and 36.6% operating margin.
OpEx & R&D Reinvestment37.1% of Rev ($24.5B)
90D Engineering Disclosures0 Published
Investor FAQ MTNB vs ABBV Key Questions & Quantitative Answers
As of Nov 19, 2026, Abbvie Inc. (ABBV) is the stronger overall head-to-head candidate over Matinas BioPharma Holdings, Inc. (MTNB) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MTNB carries a Unified Composite Score of 54.6/100 (HOLD) at $0.81 (N/M Forward P/E, 0.0% operating margin), whereas ABBV carries 53.5/100 (HOLD) at $283.54 (17.4x Forward P/E, 36.6% operating margin). Composite vs. Pillar Nuance: While MTNB currently prints a higher short-term Unified Composite Score (54.6/100 HOLD vs. ABBV 53.5/100 HOLD), ABBV captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (36.6% vs. 0.0% operating margin) and revenue trajectory (+10.3% vs. -100.0% YoY).
ABBV leads the Growth & Scale pillar: MTNB posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ABBV at +10.3% YoY revenue growth and N/A YoY earnings growth on $66.0B TTM revenue (73.7% gross margin, 36.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MTNB cumulative revenue shifted N/A while ABBV shifted +86.7%. In operating R&D and SG&A reinvestment, MTNB deploys N/A (0 90-day corporate R&D disclosures) versus 37.1% of Rev ($24.5B) (0 disclosures) for ABBV.
ABBV screens cheaper on headline valuation multiples. MTNB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABBV trades at 17.4x Forward P/E, 49.1x Trailing P/E, 0.59x PEG, and 8.7x EV/Revenue (28.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MTNB (-147.5% ROE) versus ABBV (62.3% ROE) capital efficiency.
In options market volatility and institutional positioning, MTNB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-7.20β · 147% Vol realized risk). By comparison, ABBV carries 23.4% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.57x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.02β · 20% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.